

Post-Event Report

3RD ANNUAL ADVANCES IN IMMUNO-ONCOLOGY CONGRESS

Statistics - Testimonials - Your Feedback - Resources - Photos

PLUS 2019 Event Information



99 CITY ROAD CONFERENCE CENTRE
24 - 25 MAY 2018 | LONDON, UK



WELCOME TO THE 3RD ANNUAL ADVANCES IN IMMUNO-ONCOLOGY CONGRESS POST-EVENT REPORT!

The themes for this year's Advances in Immuno-Oncology Congress were focused around finding novel immunotherapies, designing a rational combination therapy that works for the majority of cancer types as well as the development of personalised immunotherapies. We saw and heard from leading Pharma and Biotech companies sharing their knowledge and experiences across the R&D Immuno-Oncology spectrum that in turn has given other R&D professionals in attendance a lot to think about and discuss.

Alongside the highest attendance numbers to date from both delegates and sponsors, this year we introduced one new feature, which was very well received:

Breakfast Roundtable discussions, enabling attendees to interact and knowledge share with their peers on focused topics within the industry. Attendee feedback suggests that this feature was highly popular, and many participants would like more time devoted to this in 2019!

Whilst this new element of the event received excellent feedback, the familiar features were also popular. With over 40 presentations from leading industry figures and solution providers, attendees were spoilt for choice, with feedback advising the high scientific content and

opportunity to learn more about potential solutions in one place was invaluable.

With the event going into its 4th year, Oxford Global has many continued supporters and it is a pleasure to catch up with familiar faces each year and know that our event is working well for you! It's also exciting to see the continued growth of this forum with new sponsors and attendees joining us each year, and 2018 was no different with an 15% growth overall.




Read on to see more about the 2018 congress and to have a sneak peek at some of the 2019 Congress plans!

- Peter Franko, Portfolio Director



WHO DID YOU MEET AT 99 CITY ROAD CONFERENCE CENTRE?

A BREAKDOWN OF THE 3RD ANNUAL ADVANCES IN IMMUNO-ONCOLOGY ATTENDEE PROFILE:



232 ATTENDEES
15% INCREASE YEAR-ON-YEAR




55 PRESENTATIONS
+ 4 ROUNDTABLE DISCUSSIONS
+ 2 PANEL DISCUSSIONS
+ 1 WORKSHOP



24 SPONSORS



49 ONE-TO-ONE MEETINGS
SUCCESSFUL PRE-PLANNED



SPONSOR TESTIMONIALS

DELEGATE TESTIMONIALS

"The layout was good as were the talks. The networking opportunities went really well for us and over all it was a really good, productive conference."

- Director Immune Insight Limited, Consultant to Histologix Ltd, Histologix

"I appreciated the size and format of the event with long breaks for networking. There was a good mix of technology and applications in Immuno-Oncology, the event was very well focused."

- Vice President of Strategic Development, Myriad RBM

"The relatively small size of the event provided plenty of opportunity for networking with others within the Immuno-Oncology field."

- Head of Drug Discovery, Centauri Therapeutics

"The rooms were of a good size, not too big. The session on the Friday morning was particularly enjoyable for me. This is a really good way to meet other people."

- Director, Genomic Immuno-Oncology, Evaxion

"There was a very good mix of speakers, good food and good long breaks to discuss with attendees."

- Chief Scientific Officer, DJS Antibodies

"There were good talks and the programme kept to time. This was a great opportunity for networking and meeting new people."

- Commercial Development Manager, Abcam

"This was a very well organised event with an amazing effort by Oxford Global to get the 1-2-1 meetings accomplished. If anyone missed a meeting they always had arranged enough meetings for there to be a replacement."

- Manager Sales EMEA, Personalis

"There was a broad range of relevant topics from large pharma, biotech, and academia."

- Chief Scientific Officer, Covance

"I made some really important new connections at the event – especially with others from within the industry. I was impressed with the quality of the talks and I liked that I was able to move freely to attend talks in other streams."

- Chief Scientific Officer, Verastem Oncology

"The quality of the talks was excellent and they were very well suited to the audience. It was easy to navigate between streams and determining which talks to attend as similar or complimentary talks were not scheduled at the same time."

- Portfolio Manager, Immunocore

"The content of the speakers presentations was strong. The spatial arrangement of the conference, including the lunch and exhibition space, provided good opportunities to talk with delegates."

- Head of Biopharma Business Development, OncoDNA

"It was well organised and the mix of delegates was good. From a CRO Point of view I liked the Panel Discussion 'Mouse Models to Guide Decisions in the Clinic.'"

- Business Development Manager, ProQinase

"The event was very well organised and there was a great mix of topics."

- Executive Director, Therapeutic Area Head Oncology, MSD

"There was a good mix of topics and speakers as well as the opportunity to meet with vendors to find out about new technologies."

- Director Translational Sciences, Immuno-Oncology, GlaxoSmithKline



YOU SPOKE, WE LISTENED:

Delegates & Networking



You have told us that you would like to see more Academic representatives.

For 2019, you will see a 20% increase in Academic participation.



You have told us that you valued the opportunity to make connections at the event.

For 2019, you will see an increase in attendees and streams to provide you with more opportunities to network.

Programme Content



You wanted a bigger focus on biomarkers.

There will be an increased level of talks on this for 2019, with biomarkers a crucial discussion point in our Translational Immuno-Oncology and brand new Precision Medicine & Personalised Therapy streams.



You would like to hear more on T cell therapy.

This will be one of the key therapeutic strategies concentrated upon at next year's congress, from early discovery through to the clinic.



Location & Venue



You have told us that you would like to have more space available to network with your peers.

For next year's event we have booked a larger venue to ensure you have plenty of room and extra sitting spaces.

Breakfast Roundtables



Roundtables were a great success.

The programme for 2019 will have even more ways to interact with your peers on a more personal level.

ILEC CONFERENCE CENTRE

NEXT YEAR'S EVENT

20 - 21 MAY 2019

4TH ANNUAL ADVANCES IN IMMUNO- ONCOLOGY CONGRESS

Register your interest

For exhibition or sponsorship enquiries e-mail:
sponsorship@oxfordglobal.co.uk

For speaker opportunities e-mail Cerlin Roberts:
c.roberts@oxfordglobal.co.uk

For delegate attendance enquiries e-mail:
marketing@oxfordglobal.co.uk

R&D USA SERIES

If you are looking for a US-based Immuno-Oncology event, look no further than our **R&D USA Series**, taking place 11-12 October 2018 in San Diego, comprised of our **5th Annual Drug Discovery USA Congress**, **3rd Annual Biomarkers & Precision Medicine USA Congress**, and **Advances in Immuno-Oncology USA Congress**. More details can be found at:

www.oxfordglobal.co.uk/rd-us-series



You don't need to wait until future events to get involved!

Our LinkedIn and Twitter groups are an excellent way of keeping up to date on the industry and with your peers.

Follow @ImmunoOncConf on **Twitter** and join the Congress conversation with #Immuno19.

>> [Follow @ImmunoOncConf](#)

Connect and network with industry and academic peers through our **LinkedIn** group.

>> [Join our LinkedIn group](#)

Visit the congress' **Resources Page** to gain access to our complimentary resources, including Webinar Recordings, Q&A Sessions Peer-reviewed Journals, and more!

>> [Visit the Resources page](#)

THANK YOU TO OUR SPEAKERS AND SPONSORS

GOLD

abcam

NETWORK AND PROGRAMME SPONSORS



Thank you once more to all who made the 3rd Annual Advances in Immuno-Oncology Congress a success: to all attendees, speakers who presented at the event, and our sponsors above. We hope to see you again next year!



THANK YOU FOR COMING